CAMP cGMP PDE NO
| Zeile 11: | Zeile 11: | ||
{{tp|p=32497535|t=2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.|pdf=|usr=009}} | {{tp|p=32497535|t=2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.|pdf=|usr=009}} | ||
{{tp|p=32574572|t=2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.|pdf=|usr=010}} | {{tp|p=32574572|t=2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.|pdf=|usr=010}} | ||
| + | {{tp|p=32558435|t=2020. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.|pdf=|usr=011}} | ||
| + | |||
'''PDE5 Inhibitors''' | '''PDE5 Inhibitors''' | ||
{{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}} | {{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}} | ||
{{tp|p=32226695|t=ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32226695|t=ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | ||
Version vom 8. Juli 2020, 10:12 Uhr
Nitric oxide
32526061 2020. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection.
32387333 ä. Could nasal nitric oxide help to mitigate the severity of COVID-19?
32436029 2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.
32454510 2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.
32579020 2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?
32590117 2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.
PDE4 Inhibitors
32497535 2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
32574572 2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.
32558435 2020. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.
PDE5 Inhibitors
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
